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Abstract. – Background and Objectives:
Glycoproteins D (gD) and G (gG) of herpes sim-
plex virus type 1 (HSV-1) are virus envelope gly-
coproteins that are able to induce HSV-1 anti-
body production in infected persons. Therefore,
those proteins could be in interest to develop
the serodiagnostic test(s) for HSV antibody de-
tection. The aim of present study was the com-
parison of anti-gD and anti-gG antibodies in
HSV-1 infected individuals' serum samples. 
Materials and Methods: In this study, recom-
binant gD and gG were prepared and used for
western blot test to detect the antibodies against
HSV-1. 
Results: Our data showed the total gD anti-
body titer was higher than gG antibody titer in
the HSV-1 infected patient’s sera but the gG anti-
body titer was high significantly. 
Conclusions: According to our results, gD
and gG can be used for designing the diagnostic
laboratory tests to evaluate total antibody
against HSV-1 and HSV-2.
Key Words:
Herpes simplex virus type 1, Glycoprotein D, Glyco-
protein G, Western blotting.
Introduction
Herpes simplex virus type 1 (HSV-1) is an en-
veloped spherical virus with an icosahedral capsid
that is considered as an important infectious agent
in human illnesses. Viral envelope contains at least
10 glycoproteins and 2 non-glycosilated1. Two im-
portant envelope glycoproteins are glycoprotein D
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(gD) and glycoprotein G (gG) that exhibit a very
important role during the virus replication cycle2,3.
Glycoprotein D is expressed on HSV infected cel-
l’s surface and is essential for the viral infectivi-
ty4,5. Indeed, gD is a common-type antigen and
stimulates the high production of neutralizing anti-
bodies especially between HSV-1 and HSV-26-8. It
serves as a receptor binding protein for entry to
the target mammalian cells and is important in the
integration of the viral envelope and plasma mem-
brane of the cells9,10.
Glycoprotein D is an important inducer for hu-
moral and cellular immune responses against the
virus infection and it is a very conserved glycopro-
tein with more than 98 percent homology between
HSV strains3,8,9. Glycoprotein G is required for vi-
ral entry into polarized cells11. It has a role in virus
release and cell to cell virus spread. Indeed, gG in-
troduced as a candidate to develop the type specif-
ic serodiagnostic kits for HSV-1 and HSV-212.
Both gD and gG are HSV surface glycoproteins
and they are able to stimulate production of spe-
cific antibodies in infected individuals. 
The aim of this study was to determine the
level of anti-gD and anti-gG total antibodies in
HSV-1 infected sera.
Materials and Methods
Virus and Cell Lines
In this study one clinical isolate of HSV-1 was
used. This virus was isolated from labial vesicles
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of a patient and identified as HSV-1, using mon-
oclonal antibody as described previously13. HeLa
cell line as a proper cell line for HSV-1 propaga-
tion was grown in Dulbecco’s Modified Eagle
Medium (DMEM; Gibco, Carlsbad, CA, USA)
supplemented with 5% fetal bovine serum (FBS;
Gibco, Carlsbad, CA, USA) 100 IU/ml penicillin
and 100 µg/ml streptomycin at 37°C in the pres-
ence of 5% CO214.
We have used a recombinant baculovirus con-
taining HSV-1 gD gene in order to produce the
recombinant gD. The Sf9 insect cell line was
used in order to propagation of recombinant bac-
ulovirus. The cells were grown in Grace’s medi-
um supplemented with 10% FBS, 3.33 g/l lactal-
bumin hydrolysate, 3.33 g/l yeast extract and 50
µg/ml gentamycin at 26 ºC in a non-humidified
incubator.
HSV-1 Propagation
HeLa cells (From Virology Lab of Tarbiat
Modarres University) were infected by HSV-1 at
a multiplicity of infection (moi) of 0.1 plaque
forming unit/cell (PFU/cell), and viruses harvest-
ed from the growth medium when more than
75% of the cells showed the virus cytopathic ef-
fects (CPE). The titer of propagated HSV-1 was
determined using Tissue Culture Infectious Dose
50 (TCID50) method as described previously15,16. 
Virus Neutralization Test (VNT)
VNT was used for titration of HSV-1 neutral-
izing antibodies in serum samples as described
previously13.
gD and gG Preparation
Sf9 cells were infected by recombinant bac-
ulovirus containing HSV-1 gD gene at a multi-
plicity of infection (moi) of 7 and the cells were
incubated for 5 days at 26 ºC in a non-humidified
incubator. Then, the cells were scraped, 1M
phenylmethylsulfonyl fluoride (PMSF) was
added and the proteins were harvested using son-
icator (Branson, Danbury, USA). The recombi-
nant gG was prepared in E.coli and a DEAE-
Sepharose CL-6B column (Fluka, Buchs,
Switzerland) was used for its purification as de-
scribed previously12. The non-purified gD and
purified gG proteins were used in SDS-PAGE
and western blotting.
SDS-PAGE and Western Blotting
The prepared glycoproteins were mixed with
electrophoresis sample buffer (50 mM Tris pH
8.6, 10% glycerol, 2% W/V sodium dodecyl sul-
fate (SDS) (Sigma, St.Louis, MO, USA), and
0.1% bromophenol blue, (no reduced method)
and boiled for 10 min. Sodium dodecyl sulfate-
polyacryl amide gel electrophoresis (SDS-PAGE)
performed in 12% polyacrylamide. Then, the re-
combinant proteins were transferred on nitrocel-
lulose paper and blocking was done using 5%
gelatin solution. The serum samples with 1:32
anti-HSV-1 titer in virus neutralization test
(VNT) were used for the western blotting and the
dilutions of 1:200, 1:400, 1: 800 and 1:1600 were
used in the western blotting method. Antibodies
against HSV1 glycoproteins were detected by re-
acting the blots with alkaline phosphate-conju-
gated anti human antibody and visualizing by di-
aminobenzidine (DAB) as substrate17,18.
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Figure 1. A, HeLa monolayer cells. The cells are adherent with epithelial appearance. B, Cytopathic effects (CPE) of HSV-1
on the HeLa cells. The CPE includes rounding and ballooning of infected cells and the multinucleated giant cells formation
(arrow).
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mining and comparing the total antibody re-
sponses against two glycoproteins gD and gG,
1:200 to 1:1600 serial dilutions of positive sera
with anti HSV-1 antibody titer of 1:32 in VNT,
were used in Western blotting using recombi-
nant gD and gG. 
Previous studies showed gD could induce the
high titer of neutralizing antibodies but the main
problem for application of gD for serodiagnosis
is the high similarity between gD-1 from HSV-1
and gD-2 from HSV-26,8,19. Therefore, gD could
be good candidate to develop a serodiagnostic
kit for total antibody against HSV-1 and HSV-2.
The other important point is the gG can induce
less total antibodies compare to gD but the titer
of antibody is high enough for using this glyco-
protein in diagnostic tests, especially if the dif-
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Results
Figure 1A shows HeLa monolayer cells. These
cells are immortal and adherent cells with epithe-
lial appearance. The HSV-1 cytopathic effects on
HeLa cells are shown in figure 1B. CPEs of
HSV-1 on HeLa cells are included rounding and
ballooning of the infected cells and also multinu-
cleated giant cells formation.
CPEs were detected in infected cells and the
ratio of the CPE positive wells to CPE negative
wells recorded. The titer of propagated HSV-1
was 105.5 TCID50/ml. The propagated viruses
were used in VNT and antibody titer of HSV-1
was measured in serum of patients. 
Fifteen serum samples out of 100 were detect-
ed as positive for HSV-1 antibody regarding their
antibody titer which were equal or above 1:32
using VNT. The VNT determined positive sera
were evaluated using western blotting method.
The results from western blotting test using gD
recombinant protein showed that all VNT detect-
ed positive samples were positive even using
1:3200 diluted sera. 
Results from western blotting using recombi-
nant gG showed that all VNT detected positive
samples were positive but the most diluted sera
which gave us positive results was 1:400.
Discussion
Herpes simplex virus type 1 causes a wide
range of human diseases, including systemic in-
fections in infants and immunocompromised
people and localized infections such as infectious
lesions in the lips and mouth, mucosal mem-
branes, skin, cornea, reproductive organs and
central nervous system. HSV-1 is the most com-
mon cause of sporadic encephalitis in United
States. Neonatal HSV-1 infections that may be
occur in the uterus, at birth or after birth in the
untreated cases have high mortality. HSV can be
caused disseminated infections and lethal dis-
eases in immunocompromised patients1. 
It is important to note the most of surface
HSV-1 glycoproteins induces the cellular and
humoral immune responses. Although gD is the
most efficient HSV-1 glycoprotein for induc-
tion of neutralizing antibodies against the virus,
it is not clear about the efficacy of these glyco-
proteins including gD and gG for the induction
of total antibodies against the virus. For deter-
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